Abdominal Fat
Conditions
Keywords
Syneron, Velashape, ELOS, Ultrashape
Brief summary
The purpose of this study is to compare the clinical performance of the Ultrashape system with VelaShape II device for reduction of the waist.
Detailed description
UltraShape® Contour I V3 system is a non-invasive (not breaking the skin) focused ultrasound for body contouring purposesdesigned to selectively disrupt sub-dermal fat cells employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves, remain intact. There are no thermal effects. Fat-cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time. VelaShape is a non-invasive device for Body Reshaping and Cellulite Treatment. VelaShape combines controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation.
Interventions
DEVICEUltrashape
All subjects receive 3 successive Ultrashape treatments every two weeks in the anterior abdomen.
DEVICEVelashape II
All subjects receive 3 successive Velashape treatments every two weeks in the anterior abdomen.
Sponsors
Syneron Medical
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Fat thickness of at least 1.5 cm in the anterior abdominal and flanks prior to initial treatment (measurement by caliper) 2. For women of child-bearing potential: negative pregnancy test in the 24 hour period prior to enrollment and 24 hour period prior to each treatment or FU visit (measured in urine) 3. General good health confirmed by medical history and skin examination of the treated area 4. Written informed consent to participate in the study 5. Ability to comply with the requirements of the study 6. BMI≤ 30
Exclusion criteria
1. History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator, abdominal aortic aneurism 2. Current hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease or malignancy 3. Previous liposuction in the treatment areas 4. History of skin disease in the treatment area, known tendency to form keloids or poor wound healing 5. Skin lesions in the treatment area other than simple nevi on physical examination (e.g., atypical nevus, tattoo, abrasions) including depressed scars in the treatment area 6. Poor skin quality (i.e., laxity) 7. Abdominal wall diastasis or hernia on physical examination 8. Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months 9. Obesity (BMI \> 30) 10. Childbirth within the last 12 months or women who suckling a child 11. Any acute or chronic condition which, in the opinion of the Investigator, could interfere with the conduct of the study 12. Unstable weight within the last 6 months (i.e., ± 3% weight change in the prior six months) 13. Inability to comply with circumference measurement procedure (e.g., inability to held breath for the required duration) 14. Participation in another clinical study 15. Previous body contouring treatments in the treatment areas
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference in circumference reduction between baseline and follow-up visits | Base line, 2 and 12 weeks post last treatment | The primary efficacy endpoint in this trial is the statistical difference in circumference reduction between Control (baseline measurement, Vist 2 / Day 0) and two points of follow-up measurement: 2 weeks (Visit 5 / Day 42) and 12 weeks (Visit 8 / Day 112) following the last Tx session. The following procedure will be used to compute the Circumference Difference primary endpoint: |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | The duration of the study, an expected average of 5 months. | Safety will be evaluated based on the incidence and severity of adverse events caused by the treatments |
Other
| Measure | Time frame | Description |
|---|---|---|
| Subject Satisfaction Scores | 2, 4, 6, 8,10 and 12 week in a study. | Subject Satisfaction Scores using the Global Aesthetic Improvement (GAI) Scale at each treatment and follow-up time point post treatment: 2 week, 4 week, 6 week, 8 week, 10 week and 12 week in a study. |
Countries
Canada
Outcome results
None listed